ACN Newswire

Tue Nov 15

Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as In Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting

Written by ACN Newswire

Paris, France and Cambridge, Massachusetts, USA, Nov 14, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces preclinical data demonstrating that its leading radioenhancer nanoparticle, NBTXR3, actively...

ACN Newswire

Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as In Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting

What did the High Court decide in the Pell case? And what happens now?

How Australians talk about tucker is a story that'll make you want to eat the bum out of an elephant

Consumers Support Companies That Take a Stand- Horowitz Research

Liberal warns Coalition party room that sheep trade is a 'vote changing issue'

The air above Antarctica is suddenly getting warmer – here's what it means for Australia

4½ myths about sunscreen and why they're wrong

Virtual power plants are in vogue, but they can be like taking a sledgehammer to a nut

Stages 1 and 2 of the tax cuts should pass. But Stage 3 would return us to the 1950s

'New Bradfield': rerouting rivers to recapture a pioneering spirit

With Cohen and Manafort both guilty, the pressure on Trump is rising

Australia could look to New Zealand to increase the number of Indigenous academics and students